EcoDrugPlus

60s Ribosomal Protein L30-Like

Ensembl ID : ENSSTOG00000031266
Gene Symbol: LOC101977607
2 Cross references
206 Possible Orthologues:

60s Ribosomal Protein L31 Pseudogene

Ensembl ID : ENSSTOG00000024015
Gene Symbol: LOC101972698
1 Cross references
152 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSSTOG00000029048
Gene Symbol: LOC101971642
2 Cross references
45 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSTOG00000003888
Gene Symbol: ARAF
4 Cross references
191 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSTOG00000026819
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSSTOG00000004510
Gene Symbol: ADAM17
4 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSSTOG00000008876
Gene Symbol: ADAMTS5
3 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSSTOG00000002691
Gene Symbol: ADRM1
4 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSSTOG00000013484
Gene Symbol: AKT1
4 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSSTOG00000002916
Gene Symbol: AKT2
4 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSSTOG00000010595
Gene Symbol: AKT3
3 Cross references
201 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSSTOG00000002811
Gene Symbol: ALK
3 Cross references
194 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).